Drug Safety Update

Kaftrio鈻� (Ivacaftor, tezacaftor, elexacaftor): risk of psychological side effects

Psychological side effects such as anxiety, low mood, sleep disturbance, poor concentration, and forgetfulness have been infrequently reported in people with cystic fibrosis treated with Kaftrio. Healthcare professionals sho鈥�
- Therapeutic area: General practice and 2 others
- Published: 7 May 2025
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines

Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with or without anti-inflammatory maintenance therapy in patients with asthma. H鈥�
- Therapeutic area: General practice and 2 others
- Published: 24 April 2025
Fezolinetant鈻�(Veoza): risk of liver injury; new recommendations to minimise risk

Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients ta鈥�
- Therapeutic area: Dispensing GP practices and 2 others
- Published: 10 April 2025

Don鈥檛 include personal or financial information like your National Insurance number or credit card details.

What were you doing?

What went wrong?

To help us improve 51茶馆, we鈥檇 like to know more about your visit today. .

51茶馆